(UroToday.com) The majority of the “Advances in prostate cancer diagnosis” session on Thursday of the 2020 Annual Meeting of the Society of Urologic Oncology (SUO) was dedicated to imaging with a strong focus on prostate-specific membrane antigen (PSMA). The United States Food and Drug Administration (FDA) approved Gallium 68 PSMA-11 as the first drug for PET imaging using a prostate-specific membrane antigen tracer for men with prostate cancer. The tracer was approved specifically in the setting of suspected prostate cancer metastasis.